697 related articles for article (PubMed ID: 26659727)
1. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.
Zheng TJ; Lofurno ER; Melrose AR; Lakshmanan HHS; Pang J; Phillips KG; Fallon ME; Kohs TCL; Ngo ATP; Shatzel JJ; Hinds MT; McCarty OJT; Aslan JE
Am J Physiol Cell Physiol; 2021 May; 320(5):C902-C915. PubMed ID: 33689480
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
[TBL] [Abstract][Full Text] [Related]
5. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.
Hsu J; Gu Y; Tan SL; Narula S; DeMartino JA; Liao C
Immunol Lett; 2013 Feb; 150(1-2):97-104. PubMed ID: 23266841
[TBL] [Abstract][Full Text] [Related]
6. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking.
Oda A; Ikeda Y; Ochs HD; Druker BJ; Ozaki K; Handa M; Ariga T; Sakiyama Y; Witte ON; Wahl MI
Blood; 2000 Mar; 95(5):1663-70. PubMed ID: 10688822
[TBL] [Abstract][Full Text] [Related]
7. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib-related bleeding: pathogenesis, clinical implications and management.
Aguilar C
Blood Coagul Fibrinolysis; 2018 Sep; 29(6):481-487. PubMed ID: 29995658
[TBL] [Abstract][Full Text] [Related]
10. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
[TBL] [Abstract][Full Text] [Related]
11. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.
Quek LS; Bolen J; Watson SP
Curr Biol; 1998 Oct; 8(20):1137-40. PubMed ID: 9778529
[TBL] [Abstract][Full Text] [Related]
12. Differential Regulation of GPVI-Induced Btk and Syk Activation by PKC, PKA and PP2A in Human Platelets.
Zhang P; Solari FA; Heemskerk JWM; Kuijpers MJE; Sickmann A; Walter U; Jurk K
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175486
[TBL] [Abstract][Full Text] [Related]
13. Tec regulates platelet activation by GPVI in the absence of Btk.
Atkinson BT; Ellmeier W; Watson SP
Blood; 2003 Nov; 102(10):3592-9. PubMed ID: 12842985
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry.
Cheung HYF; Moran LA; Sickmann A; Heemskerk JWM; Garcia Á; Watson SP
Platelets; 2022 Nov; 33(8):1293-1300. PubMed ID: 35535424
[TBL] [Abstract][Full Text] [Related]
15. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
16. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
Dobie G; Kuriri FA; Omar MMA; Alanazi F; Gazwani AM; Tang CPS; Sze DM; Handunnetti SM; Tam C; Jackson DE
Blood Adv; 2019 Dec; 3(24):4298-4311. PubMed ID: 31869418
[TBL] [Abstract][Full Text] [Related]
18. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Uckun FM; Vassilev A; Bartell S; Zheng Y; Mahajan S; Tibbles HE
Leuk Lymphoma; 2003 Sep; 44(9):1569-77. PubMed ID: 14565661
[TBL] [Abstract][Full Text] [Related]
19. Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
Busygina K; Denzinger V; Bernlochner I; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Aug; 119(8):1212-1221. PubMed ID: 31087308
[TBL] [Abstract][Full Text] [Related]
20. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
